April 15, 2025
A California federal judge on Tuesday denied Biogen's bid for summary judgment in a high-stakes contract fight with Roche Holding AG subsidiary Genentech over patent royalties on multiple sclerosis drug sales, saying during a hearing that there's a material dispute over the contract's language and the case will be tried in June.
March 01, 2023
Biogen Inc. has broken a licensing agreement with Roche Holding AG subsidiary Genentech Inc. by refusing to pay any more royalties from sales of its immunosuppressive drug Tysabri for the treatment of multiple sclerosis and Crohn's disease, according to a lawsuit filed Tuesday in California federal court.